292 related articles for article (PubMed ID: 32698638)
1. Does inappropriate initial antibiotic therapy affect in-hospital mortality of patients in the emergency department with
Chen FC; Ho YN; Cheng HH; Wu CH; Change MW; Su CM
Int J Immunopathol Pharmacol; 2020; 34():2058738420942375. PubMed ID: 32698638
[TBL] [Abstract][Full Text] [Related]
2. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
3. Influence of Antimicrobial Stewardship and Molecular Rapid Diagnostic Tests on Antimicrobial Prescribing for Extended-Spectrum Beta-Lactamase- and Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in Bloodstream Infection.
Kunz Coyne AJ; Casapao AM; Isache C; Morales J; McCarter YS; Jankowski CA
Microbiol Spectr; 2021 Oct; 9(2):e0046421. PubMed ID: 34704795
[TBL] [Abstract][Full Text] [Related]
4. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
[TBL] [Abstract][Full Text] [Related]
5. Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Positive K. pneumoniae and E. coli: Comparison of Severity of Sepsis, Delay of Anti-Infective Therapy and ESBL Genotype.
Sakellariou C; Gürntke S; Steinmetz I; Kohler C; Pfeifer Y; Gastmeier P; Schwab F; Kola A; Deja M; Leistner R
PLoS One; 2016; 11(7):e0158039. PubMed ID: 27442425
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
[TBL] [Abstract][Full Text] [Related]
8. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection.
Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Bilker WB; Lautenbach E
Arch Intern Med; 2005 Jun; 165(12):1375-80. PubMed ID: 15983286
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections.
Superti SV; Augusti G; Zavascki AP
Rev Inst Med Trop Sao Paulo; 2009; 51(4):211-6. PubMed ID: 19739001
[TBL] [Abstract][Full Text] [Related]
10. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort.
Leistner R; Gürntke S; Sakellariou C; Denkel LA; Bloch A; Gastmeier P; Schwab F
Infection; 2014 Dec; 42(6):991-7. PubMed ID: 25100555
[TBL] [Abstract][Full Text] [Related]
11. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
12. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
14. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.
Joo EJ; Park DA; Lee NR; Moon SY; Choi JK; Ko JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2093-2100. PubMed ID: 28643188
[TBL] [Abstract][Full Text] [Related]
15. Impact of a clonal outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK.
Webster DP; Young BC; Morton R; Collyer D; Batchelor B; Turton JF; Maharjan S; Livermore DM; Bejon P; Cookson BD; Bowler IC
J Antimicrob Chemother; 2011 Sep; 66(9):2126-35. PubMed ID: 21693458
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing
Liang T; Xu C; Cheng Q; Tang Y; Zeng H; Li X
Microb Drug Resist; 2021 Jun; 27(6):800-808. PubMed ID: 33232654
[No Abstract] [Full Text] [Related]
17. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
[TBL] [Abstract][Full Text] [Related]
19. [Impact of extended-spectrum β-lactamase on clinical outcome and medical cost in patients with bloodstream infection due to Klebsiella pneumoniae].
Li JQ; Tang CQ; Wang H; Ji SZ; Lü KY; Xiao SC; Deng AM; Huang Y; Xia ZF
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1903-6. PubMed ID: 27373357
[TBL] [Abstract][Full Text] [Related]
20. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Chopra T; Marchaim D; Veltman J; Johnson P; Zhao JJ; Tansek R; Hatahet D; Chaudhry K; Pogue JM; Rahbar H; Chen TY; Truong T; Rodriguez V; Ellsworth J; Bernabela L; Bhargava A; Yousuf A; Alangaden G; Kaye KS
Antimicrob Agents Chemother; 2012 Jul; 56(7):3936-42. PubMed ID: 22547616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
